The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis
Thalidomide maintenance has the potential to modulate residual multiple myeloma (MM) after an initial response. This trial compared the effect of thalidomide maintenance and no maintenance on progression-free survival (PFS) and overall survival (OS) in MM patients. After intensive or nonintensive induction therapy, 820 newly diagnosed MM patients were randomized to open-label thalidomide maintenance until progression, or no maintenance. Interphase FISH (iFISH) analysis was performed at study entry. Median PFS was significantly longer with thalidomide maintenance (log-rank P < .001). Median OS was similar between regimens (log-rank P = .40). Patients with favorable iFISH showed improved PFS (P = .004) and a trend toward a late survival benefit. Patients with adverse iFISH receiving thalidomide showed no significant PFS benefit and worse OS (P = .009). Effective relapse therapy enhanced survival after progression, translating into a significant OS benefit. Meta-analysis of this and other studies show a significant late OS benefit (P < .001, 7-year difference hazard ratio = 12.3; 95% confidence interval, 5.5-19.0). Thalidomide maintenance significantly improves PFS and can be associated with improved OS. iFISH testing is important in assessing the clinical impact of maintenance therapy. Overview analysis demonstrated that thalidomide maintenance was associated with a significant late OS benefit.
7-15
Morgan, Gareth J.
d285dcf8-ac2c-4fe0-acf9-4787eb025939
Gregory, Walter M.
4a7a4c5a-0a88-4ba2-8f08-0c035dd0b6db
Davies, Faith E.
9ea9e143-ac51-431b-8cb5-57b8dc0a38af
Bell, Sue E.
4a926468-0ec4-4191-9842-5e9117d07883
Szubert, Alexander J.
f83d6436-08ec-46ea-878a-14fa54b27dc0
Brown, Julia M.
cc31c369-afef-4309-831a-ef4cafb3f365
Coy, Nuria N.
4a71f4b5-6bbb-4522-bfa9-c0f44363d53b
Cook, Gordon
4fe17be9-5e4e-4a58-a09a-b76f07f410f4
Russell, Nigel H.
c7782520-de9a-41fd-9512-2fbcd26f0401
Rudin, Claudius
187e4beb-781d-4ffc-b8a1-83df6ed306e8
Roddie, Huw
1196845f-22f3-4240-bc41-2a2035721c9d
Drayson, Mark T.
282a00f4-8edf-4075-a83c-272ffcce53e8
Owen, Roger G.
5846329e-f7a0-44d9-ac7a-717fb76ff9b5
Ross, Fiona M.
ec0958f8-b992-4e4a-b7e3-c474600390ba
Jackson, Graham H.
82e8cc2d-7530-4b02-8f92-176f47451839
Child, J. Anthony
1a7a739b-5295-4818-a455-3c67d9020abc
5 January 2012
Morgan, Gareth J.
d285dcf8-ac2c-4fe0-acf9-4787eb025939
Gregory, Walter M.
4a7a4c5a-0a88-4ba2-8f08-0c035dd0b6db
Davies, Faith E.
9ea9e143-ac51-431b-8cb5-57b8dc0a38af
Bell, Sue E.
4a926468-0ec4-4191-9842-5e9117d07883
Szubert, Alexander J.
f83d6436-08ec-46ea-878a-14fa54b27dc0
Brown, Julia M.
cc31c369-afef-4309-831a-ef4cafb3f365
Coy, Nuria N.
4a71f4b5-6bbb-4522-bfa9-c0f44363d53b
Cook, Gordon
4fe17be9-5e4e-4a58-a09a-b76f07f410f4
Russell, Nigel H.
c7782520-de9a-41fd-9512-2fbcd26f0401
Rudin, Claudius
187e4beb-781d-4ffc-b8a1-83df6ed306e8
Roddie, Huw
1196845f-22f3-4240-bc41-2a2035721c9d
Drayson, Mark T.
282a00f4-8edf-4075-a83c-272ffcce53e8
Owen, Roger G.
5846329e-f7a0-44d9-ac7a-717fb76ff9b5
Ross, Fiona M.
ec0958f8-b992-4e4a-b7e3-c474600390ba
Jackson, Graham H.
82e8cc2d-7530-4b02-8f92-176f47451839
Child, J. Anthony
1a7a739b-5295-4818-a455-3c67d9020abc
Morgan, Gareth J., Gregory, Walter M., Davies, Faith E., Bell, Sue E., Szubert, Alexander J., Brown, Julia M., Coy, Nuria N., Cook, Gordon, Russell, Nigel H., Rudin, Claudius, Roddie, Huw, Drayson, Mark T., Owen, Roger G., Ross, Fiona M., Jackson, Graham H. and Child, J. Anthony
(2012)
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.
Blood, 119 (1), .
(doi:10.1182/blood-2011-06-357038).
(PMID:22021371)
Abstract
Thalidomide maintenance has the potential to modulate residual multiple myeloma (MM) after an initial response. This trial compared the effect of thalidomide maintenance and no maintenance on progression-free survival (PFS) and overall survival (OS) in MM patients. After intensive or nonintensive induction therapy, 820 newly diagnosed MM patients were randomized to open-label thalidomide maintenance until progression, or no maintenance. Interphase FISH (iFISH) analysis was performed at study entry. Median PFS was significantly longer with thalidomide maintenance (log-rank P < .001). Median OS was similar between regimens (log-rank P = .40). Patients with favorable iFISH showed improved PFS (P = .004) and a trend toward a late survival benefit. Patients with adverse iFISH receiving thalidomide showed no significant PFS benefit and worse OS (P = .009). Effective relapse therapy enhanced survival after progression, translating into a significant OS benefit. Meta-analysis of this and other studies show a significant late OS benefit (P < .001, 7-year difference hazard ratio = 12.3; 95% confidence interval, 5.5-19.0). Thalidomide maintenance significantly improves PFS and can be associated with improved OS. iFISH testing is important in assessing the clinical impact of maintenance therapy. Overview analysis demonstrated that thalidomide maintenance was associated with a significant late OS benefit.
This record has no associated files available for download.
More information
Submitted date: 6 June 2011
e-pub ahead of print date: 20 October 2011
Published date: 5 January 2012
Organisations:
Human Development & Health
Identifiers
Local EPrints ID: 337684
URI: http://eprints.soton.ac.uk/id/eprint/337684
ISSN: 0006-4971
PURE UUID: f01ebdfb-2839-4cf6-bf52-0838bd493339
Catalogue record
Date deposited: 02 May 2012 11:37
Last modified: 14 Mar 2024 10:57
Export record
Altmetrics
Contributors
Author:
Gareth J. Morgan
Author:
Walter M. Gregory
Author:
Faith E. Davies
Author:
Sue E. Bell
Author:
Alexander J. Szubert
Author:
Julia M. Brown
Author:
Nuria N. Coy
Author:
Gordon Cook
Author:
Nigel H. Russell
Author:
Claudius Rudin
Author:
Huw Roddie
Author:
Mark T. Drayson
Author:
Roger G. Owen
Author:
Fiona M. Ross
Author:
Graham H. Jackson
Author:
J. Anthony Child
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics